A corporate venture arm of a company specializing in infection prevention technology, primarily in the hospital setting, is interested in strategic investments and acquisitions, spanning benchtop proof of concept to businesses selling products that are on the market. Within the area of infection prevention and control, The firm will consider digital health, diagnostics and medical device technologies that relate to infection, but will not invest in pharmaceutical therapeutics. Investments can range from less than $1M, up to enterprise scale acquisitions. The firm will invest globally.
The firm is only interested in digital health, diagnostics and medical device technologies that address infection prevention and control, with a focus on healthcare acquired infection. These technologies can include track and trace, contact tracing, prevention and predictive technologies, diagnosis, identification of best treatments and non-drug intervention, among others.
The firm will only make strategic investments that align with the firm. The firm is an active investor, and will typically take a board seat after investing.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Leave a Reply